1st Aug 2007 11:47
Taihua Plc01 August 2007 Taihua plc ("Taihua" or the "Company") Update Taihua announces today that it has forwarded all current data and documentationon its anti -cancer compound, paclitaxel, to UK-based Advocates Limited("Advocates") for review. This documentation has been compiled for the purposeof obtaining European Good Manufacturing Practice ("GMP") and Certificate OfSuitability approvals ("COS"). Advocates is a European Regulatory Affairs agency which Taihua is in the processof appointing to facilitate onward submission of the data to the Europeanregulators. Once Advocates has completed the review, Advocates will submit, on behalf ofTaihua, the applications for regulatory approval. A further detailed timetable for application submission will be announced in duecourse. For further information please contact: David Youngman/Katy Mitchell, WH Ireland Limited +44 161 832 2174 Mike Wyllie, Chief Scientific Officer, Taihua plc +44 1795 597330 This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
TAIH.L